Table 2.
pMHC ligand | 2C TCR | Kass, (M−1⋅s−1 × 103) | Kdiss, s−1 × 10−2 | Kd, μM |
---|---|---|---|---|
Ld-p2Ca | C-AB treated | 8.30 ± 1.45 | 2.7 ± 0.4 | 3.3 ± 0.4 |
Ld-p2Ca | Deglycosylated | 9.40 ± 2.10 | 1.5 ± 0.2 | 1.6 ± 0.1 |
Ld-QL9 | C-AB treated | 6.35 ± 0.60 | 2.5 ± 0.4 | 3.9 ± 0.2 |
Ld-QL9 | Deglycosylated | 6.12 ± 0.65 | 1.2 ± 0.1 | 2.0 ± 0.2 |
Ld-MCMV | C-AB treated | NM | NM | NM |
Ld-MCMV | Deglycosylated | NM | NM | NM |
Kb-dEV8 | C-AB treated | 2.20 ± 0.45 | 18.5 ± 2.0 | 84.1 ± 12.0 |
Kb-SIYR | C-AB treated | 2.35 ± 0.85 | 7.5 ± 2.1 | 31.9 ± 6.2 |
Kb-VSV | C-AB treated | NM | NM | NM |
Kbm3-dEV8 | C-AB treated | 0.85 ± 0.15 | 4.8 ± 0.4 | 56.5 ± 8.1 |
Kbm3-SIYR | C-AB treated | 2.65 ± 0.15 | 7.8 ± 0.9 | 29.4 ± 3.2 |
Kbm3-VSV | C-AB treated | NM | NM | NM |
For the 2C TCR, C-AB indicates that the 2C has been carboxypeptidase A and B treated to trim the C-terminal tails, and deglycosylated indicates that the 2C TCR was expressed in the presence of tunicamycin and therefore was free of N-linked glycosylation (see Methods). Measurements were made by surface plasmon resonance on a BIAcore 2000 machine as detailed in Materials and Methods. NM, not measurable.